Neuroprotection Market Size

Neuroprotection Market size was valued at around USD 38.3 billion in 2023 and is estimated to reach over USD 70.7 billion by 2032. Neuroprotection refers to substances or interventions aimed at safeguarding neuron structure and function in the brain and nervous system. Its goal is to hinder the progression of neurodegenerative diseases, reduce injury damage, and enhance overall nervous system health. The global prevalence of neurological disorders, such as Alzheimer's, Parkinson's, and multiple sclerosis, is on the rise due to factors such as aging populations, lifestyle changes, and improved diagnostic methods.

According to Alzheimer's Disease International (ADI), the global dementia population exceeded 55 million in 2020. Projections suggest it will almost double every 20 years, reaching 78 million by 2030 and 139 million by 2050, with the majority of this rise occurring in developing countries. Currently, 60% of people with dementia are in low and middle-income nations, expected to increase to 71% by 2050. These conditions cause progressive neuron damage and impaired nervous system function, leading to a growing demand for neuroprotection treatments.

Growing investments in research and development by pharmaceutical companies, academic institutions, and government agencies are driving innovation in neuroprotection therapeutics, particularly for conditions such as Alzheimer's, and Parkinson’s disease therapeutics. This leads to the development of novel drugs, therapies, and technologies targeting neuroprotection, thus expanding the market.

Neuroprotection Market Trends

The global population is aging rapidly, with a significant increase in the proportion of elderly individuals in many countries. Aging is a major risk factor for neurodegenerative diseases and age-related cognitive decline, leading to a higher prevalence of conditions such as Alzheimer's and Parkinson's diseases.

For instance, according to the World Health Organization (WHO), by 2030, one-sixth of the global population will be aged 60 or older, increasing from 1 billion in 2020 to 1.4 billion. By 2050, the number of individuals aged 60 and above is expected to double to 2.1 billion, with the number of those aged 80 or older tripling to 426 million. Thus, as the elderly population grows, there is a corresponding rise in demand for neuroprotection therapies to address age-related neurological disorders and maintain cognitive function in older adults.

• Advances in novel drug delivery systems have greatly enhanced the efficacy and specificity of neuroprotection treatments.
  
• Traditional drug delivery methods face challenges in effectively targeting drugs to the brain while minimizing systemic side effects. However, technological innovations such as nanotechnology-based drug delivery which is estimated to reach USD 308.4 billion by 2032 systems, implantable drug delivery devices, and targeted drug delivery techniques utilizing biomaterials or nanotechnology allow for precise and controlled delivery of neuroprotection agents to the central nervous system.
  
• These advancements improve drug bioavailability, enhance therapeutic efficacy, and reduce the risk of adverse effects, thereby stimulating the development and adoption of neuroprotection treatments.
  

Neuroprotection Market Analysis

Learn more about the key segments shaping this market

Download Free Sample

Based on product, the market is segmented into antioxidants, apoptosis inhibitors, anti-inflammatory agents, glutamate antagonists, metal ion chelators, antidepressants, stimulants, neurotrophic factors (NTFs), and other products. The antioxidants segment is estimated to account for USD 14.7 billion by 2032.

• Antioxidants play a vital role in safeguarding neurons from oxidative stress, a major contributor to neurodegenerative diseases like Alzheimer's and Parkinson's.
  
• As these conditions continue to rise globally, there is heightened demand for neuroprotection treatments, bolstering the market for antioxidants.
  
• Additionally, ongoing research underscores their potential in slowing disease progression and preserving cognitive function, spurring investment in antioxidant-based therapies by pharmaceutical and biotech companies.
  

Learn more about the key segments shaping this market

Download Free Sample

Based on route of administration, the neuroprotection market is segmented into oral, intravenous, and other routes of administration. The oral segment held a substantial revenue of USD 24.9 billion in 2023.

• Oral administration offers convenience and encourages patient compliance, thus promoting widespread adoption. Moreover, advancements in pharmaceutical formulations have improved the efficacy, bioavailability, and stability of oral neuroprotection agents.
  
• Sustained-release formulations enable prolonged drug delivery, ensuring therapeutic levels for neuroprotection. Additionally, the wide range of available medications targeting various neurological conditions such as anti-inflammatory drugs, and antidepressants drugs further boosts the segment's growth.
  

Based on application, the neuroprotection market is segmented into neurodegenerative diseases, stroke and ischemic injury, traumatic brain injury (TBI), depression and bipolar disorders, spinal cord injury, and other neurological disorders. The neurodegenerative diseases segment held a substantial revenue of USD 11.8 billion in 2023.

• Neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's diseases represent significant and growing global health concerns, with increasing prevalence due to aging populations and lifestyle factors.
  
• Thus, there is heightened demand for effective treatments to slow disease progression and alleviate symptoms, fueling investment and innovation in neuroprotection therapies targeting these conditions.
  
• The complexity and severity of neurodegenerative diseases necessitate multi-faceted treatment approaches, including neuroprotection agents that can preserve neuronal function and integrity.
  
• The neurodegenerative diseases segment benefits from a wide range of neuroprotection products tailored to address specific mechanisms of neuronal damage and degeneration associated with these conditions, including antioxidants, anti-inflammatory agents, and neurotrophic factors.
  

Based on distribution channel, the neuroprotection market is segmented into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. The hospital pharmacies segment is anticipated to reach USD 30.4 billion by 2032 in the market, primarily due to its pivotal role in providing access to essential medications for patients with neurological disorders.

• Hospitals serve as primary treatment centers for such conditions, offering comprehensive care and a wide range of neuroprotection drugs.
  
• Patients and physicians prefer hospital pharmacies for their close monitoring and supervision of treatments, ensuring optimal care delivery. Additionally, hospitals' purchasing power and infrastructure further propel the revenue in this segment, enabling competitive pricing and safe medication distribution.
  

Looking for region specific data?

Download Free Sample

In 2023, North America held a significant market share of 40.6% in the neuroprotection market and is predicted to witness substantial market growth.

• North America boasts advanced healthcare infrastructure and research facilities, facilitating the development and adoption of innovative neuroprotection therapies.
  
• Additionally, the region has a high prevalence of neurological disorders, including Alzheimer's and Parkinson's diseases, driving the demand for neuroprotection treatments.
  
• Favorable regulatory frameworks and robust investment in healthcare contribute to the rapid introduction and commercialization of new neuroprotection drugs and technologies.
  
• Furthermore, increased awareness among healthcare professionals and patients regarding the benefits of neuroprotection interventions further stimulates market growth.
  

Neuroprotection Market Share

The neuroprotection industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.

Neuroprotection Market Companies

Some of the eminent market participants operating in the neuroprotection industry include:

• AbbVie Inc.
• Biogen Inc.
• Dr. Reddy’s Laboratories Ltd.
• Eli Lilly and Company
• GSK plc
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Limited
  

Neuroprotection Industry News:

• In December 2023, AbbVie Inc. acquired Cerevel Therapeutics and its extensive neuroscience pipeline, which included multiple clinical-stage and preclinical candidates with potential applications in diseases such as schizophrenia, Parkinson's disease (PD), and mood disorders. This strategic move enhanced AbbVie's neuroscience portfolio by incorporating a diverse array of high-quality assets.
  
• In July 2023, Biogen Inc. acquired Reata Pharmaceuticals, Inc., a company specializing in therapeutics for neurologic diseases. Reata's SKYCLARYS (omaveloxolone) is the first FDA-approved treatment for Friedreich's ataxia in the U.S. This acquisition enhanced Biogen's neuroscience product portfolio, providing a competitive edge in the market.
  

The neuroprotection market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Antioxidants
• Apoptosis inhibitors
• Anti-inflammatory agents
• Glutamate antagonists
• Metal ion chelators
• Antidepressants
• Stimulants
• Neurotrophic factors (NTFs)
• Other products

Market, By Route of Administration

• Oral
• Intravenous
• Other routes of administration

Market, By Application

• Neurodegenerative diseases
• Stroke and ischemic injury
• Traumatic brain injury (TBI)
• Depression and bipolar disorders
• Spinal cord injury
• Other applications 

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Drug stores
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa